Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q482044> ?p ?o }
Showing triples 1 to 67 of
67
with 100 triples per page.
- Q482044 subject Q22695562.
- Q482044 subject Q7111758.
- Q482044 subject Q7164690.
- Q482044 subject Q8401081.
- Q482044 subject Q8760194.
- Q482044 abstract "Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company is engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces three drugs: Symlin (pramlintide acetate), Byetta (exenatide) and Bydureon (exenatide extended-release). On February 4, 2014, the U.S. FDA approved Myalept (metreleptin), an analog of human leptin, as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy.In July 2012, Bristol-Myers Squibb announced it would acquire Amylin Pharmaceuticals for $5.3 billion.In December 2013, Amylin was acquired by AstraZeneca.".
- Q482044 assets "1.73".
- Q482044 equity "423.0".
- Q482044 foundingYear "1987".
- Q482044 industry Q7108.
- Q482044 location Q16552.
- Q482044 location Q30.
- Q482044 netIncome "-186.0".
- Q482044 numberOfEmployees "1900".
- Q482044 operatingIncome "-173.0".
- Q482044 product Q2062094.
- Q482044 product Q417762.
- Q482044 revenue "758.0".
- Q482044 type Q1589009.
- Q482044 wikiPageExternalLink pr?s=amln.
- Q482044 wikiPageExternalLink www.amylin.com.
- Q482044 wikiPageWikiLink Q12174.
- Q482044 wikiPageWikiLink Q12206.
- Q482044 wikiPageWikiLink Q14851942.
- Q482044 wikiPageWikiLink Q1589009.
- Q482044 wikiPageWikiLink Q16552.
- Q482044 wikiPageWikiLink Q17143468.
- Q482044 wikiPageWikiLink Q204711.
- Q482044 wikiPageWikiLink Q2062094.
- Q482044 wikiPageWikiLink Q22695562.
- Q482044 wikiPageWikiLink Q266423.
- Q482044 wikiPageWikiLink Q30.
- Q482044 wikiPageWikiLink Q417762.
- Q482044 wikiPageWikiLink Q4917.
- Q482044 wikiPageWikiLink Q7108.
- Q482044 wikiPageWikiLink Q7111758.
- Q482044 wikiPageWikiLink Q7164690.
- Q482044 wikiPageWikiLink Q731938.
- Q482044 wikiPageWikiLink Q8401081.
- Q482044 wikiPageWikiLink Q8760194.
- Q482044 assets "US$1.73B".
- Q482044 equity "US$423M".
- Q482044 foundation "1987".
- Q482044 homepage www.amylin.com.
- Q482044 industry Q7108.
- Q482044 location Q16552.
- Q482044 location Q30.
- Q482044 name "Amylin Pharmaceuticals".
- Q482044 netIncome "US$-186M".
- Q482044 numEmployees "1900".
- Q482044 operatingIncome "US$-173M".
- Q482044 products "Byetta".
- Q482044 products "Symlin".
- Q482044 revenue "US$758M".
- Q482044 type Q1589009.
- Q482044 type Organization.
- Q482044 type Agent.
- Q482044 type Company.
- Q482044 type Organisation.
- Q482044 type Agent.
- Q482044 type SocialPerson.
- Q482044 type Thing.
- Q482044 type Q43229.
- Q482044 comment "Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company is engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces three drugs: Symlin (pramlintide acetate), Byetta (exenatide) and Bydureon (exenatide extended-release). On February 4, 2014, the U.S.".
- Q482044 label "Amylin Pharmaceuticals".
- Q482044 homepage www.amylin.com.
- Q482044 name "Amylin Pharmaceuticals".